CoChat

In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates

The DOI matches its Crossref record; 66 of the 72 references it cites were found in a registry or an index.

Abstract

The central type benzodiazepine receptor (BDZr), an allosteric modulatory site of the GABAA receptor-anion channel, has been shown in vitro to respond to drugs with positive efficacy (agonists), zero efficacy (competitive antagonists) and drugs with negative efficacy (inverse agonists). However, this general concept of the function of BDZr drugs has rarely been assessed in intact living brain. We report here in on a non-invasive in vivo assessment of the intrinsic efficacies of BDZr drugs in the brain of non-human primates. We have performed an in vivo simultaneous determination of fractional BDZr occupancy and the resulting pharmacological efficacies of the full agonist diazepam, the partial agonist bretazenil, the antagonist flumazenil (Ro15-1788), the partial inverse agonist Ro15-4513 and the full inverse agonist methyl beta-carboline-3-carboxylate (beta-CCM). Positron emission tomography (PET) was used to estimate fractional BDZr occupancy measured as the in vivo displacement in the brain of the positron emitter radioligand, [11C]flumazenil. Simultaneously, the proconvulsant or anticonvulsant efficacies of the BDZr drugs were measured as their abilities to facilitate or counteract the central effects of an infusion of pentylenetetrazol, a non-competitive GABA antagonist acting on the picrotoxin site of the receptor complex. This was measured using electroencephalographic recording (EEG). Our results show that, in vivo, the fractional receptor occupancy by a given drug is perfectly correlated with its resulting graded pharmacological effects, as predicted from the competitive drug receptor interaction theory. Furthermore, the slope of the relationship between fractional receptor occupancies and the resulting pharmacological effects (an index of intrinsic efficacy) strictly depends on the BDZr ligand considered. Diazepam displayed a strong positive intrinsic efficacy, and, in contrast, beta-CCM a marked negative one. Between these two extremes, the partially active drugs bretazenil and Ro15-4513, which required a large fractional receptor occupancy to produce significant anti- or proconvulsant effects, respectively, displayed only a weak intrinsic efficacy. Flumazenil did not produce any significant pharmacological effect. We observed that the in vivo intrinsic efficacies of diazepam, flumazenil and beta-CCM correlate with their intrinsic efficacies as measured by their modulatory effects on the GABA-dependent membrane chloride conductance in vitro. Thus, the intrinsic efficacies measured using PET and EEG are likely to reflect the different in vivo abilities of BDZr drugs to induce or stabilize the GABAA-benzodiazepine chloride channel in a given conformation.(ABSTRACT TRUNCATED AT 400 WORDS)

Overview

Integrity signals

Registry

Crossref · 10.1016/0006-8993(91)90131-e

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 5

  1. Bonnetti, 1985, The partial inverse benzodiazepine agonist Ro15-4513 antagonizes acute ethanol effects in mice and rats, Br. J. Pharmacol., 86, 463P
  2. Frey, 1988, Muscarinic receptors imaging in human brain using [11C]scopolamine and positron emission tomography, J. Nucl. Med., 29, 808
  3. Furchgott, 1966, The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes, Adv. Drug. Res., 3, 21
  4. Haefely, 1985, Recent advances in molecular pharmacology of benzodiazepine receptors and in the structure-activity relationships of their agonists and antagonists, Vol. 14, 165
  5. Mazière, 1983, 11C-Ro15-1788 et11C-Flunitrazepam, deux coordinats pour l'etude par tomographie par positons des sites de liaison des benzodiazepines, C.R. Acad. Sci., 296, 871

Cited by

See all 37

Metadata

Authors
Brouillet, E., Chavoix, C., Bottlaender, M., Khalili-Varasteh, M., Hantraye, P., Fournier, D., Dodd, R. H., & Mazière, M.
Corresponding author
Mazière, Mariannick
Venue
Brain Research
Publisher
Elsevier BV
Published
1991-08
Volume
557
Issue
1-2
Pages
167-176
ISSN
0006-8993 (ISSN-L)
OpenAlex
W2051214011
Cited by
37
References
72
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2021: 1 · 2019: 1 · 2014: 1
FWCI
0.52
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Brain Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Fondation de l'Avenir pour la Recherche Médicale Appliquée
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
Keywords
benzodiazepine receptor, GABAergic neurotransmission, GABAA receptor, inverse agonists, partial agonists, intrinsic efficacy, receptor occupancy, diazepam, flumazenil, Ro 15-4513, bretazenil, pentylenetetrazole, anticonvulsant activity, proconvulsant effects, non-human primates, 11C-flumazenil PET, EEG, allosteric modulation, benzodiazepine antagonists, benzodiazepine receptor agonists
MeSH terms
Animals, Azides, Benzodiazepines, Benzodiazepinones, Binding, Competitive, Carbolines, Cerebral Cortex, Diazepam, Electroencephalography, Flumazenil, gamma-Aminobutyric Acid, Ligands, Male, Synaptic Transmission, Papio, Pentylenetetrazole, Receptors, GABA-A, Seizures, Tomography, Emission-Computed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.